Biomimetic Peptides for the Treatment of Cancer

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Discovery

Background:

• Cancer is a leading global cause of death, necessitating novel therapies with enhanced specificity and reduced toxicity.
• Cancer cells exhibit distinct molecular profiles, including surface proteins, scaffold proteins, and signaling molecules, differentiating them from normal cells.
• Tumor microenvironment interactions, involving diverse cell populations and soluble factors, are crucial for cancer progression and represent therapeutic targets.

Purpose of the Study:

• To review current strategies employing biomimetic peptides (BPs) for tumor targeting.
• To categorize BPs based on their molecular targets: cell-surface molecules, intracellular molecules, and cancer cell-tumor microenvironment interactions.
• To analyze the potential of BPs as a new class of therapeutics in oncology.

Main Methods:

• Literature review of existing research on biomimetic peptides in cancer therapy.
• Classification of BPs based on their specific targeting mechanisms and molecular interactions.
• Analysis of the advantages and challenges associated with BP-based cancer treatments.

Main Results:

• Biomimetic peptides are designed to emulate natural protein functions for therapeutic applications.
• BPs can be engineered to target specific cancer cell components or modulate the tumor microenvironment.
• Three main categories of BPs exist: those targeting cell-surface molecules, intracellular targets, and cancer cell-tumor microenvironment communications.

Conclusions:

• Biomimetic peptides represent a promising approach for developing targeted cancer therapies with potentially lower toxicity.
• Further research into BP design and delivery systems is crucial for clinical translation.
• Targeting cancer-specific molecules and the tumor microenvironment with BPs holds significant potential for advancing oncology treatments.